ClinicalTrials.gg
CompletedNCT04386044Updated May 7, 2021

Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients

An observational study in COVID-19 and Vitamin D Deficiency, sponsored by Tameside General Hospital. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-07.

Sponsored by Tameside General Hospital · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
986
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 340 studies in COVID-19 with a site in United Kingdom — 17 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · United Kingdom.

Enrollment
53rd of 167
986 · median 296
Started
2020
with 191 others
Observational
167 of 340
9 open now
Registered
60th of 340
by date

Among the 340 studies in COVID-19 with a site in United Kingdom, this one is the 53rd largest by enrollment of the 167 observational ones that give a count, is one of 192 that started in 2020, is one of 167 observational ones, and was the 60th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

17 of the 340 studies in COVID-19 with a site in United Kingdom are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 340 studies in COVID-19 with a site in United Kingdom, or all of them as a file.
02

Study summary

The 2019 novel coronavirus disease (COVID-2019) pandemic is an enormous health issue of worldwide scale. Prevention and/or treatment with a widely-available and already-licensed product such as vitamin D (cholecalciferol) could have a large impact on healthcare worldwide. Given ethnic variation in vitamin D production, this could help to address the discrepancies in how people of different ethnicities are affected by COVID-19. There are currently no published studies analysing either individual-level evidence on the effect of vitamin D status on COVID-19 outcomes, or any prospective studies planning on following-up patients with reference to vitamin D and COVID-19 infection.

The study will have 2 arms. Arm 1 will recruit patients hospitalised with COVID-19. Vitamin D levels will be measured in these patients and compared with outcome measures of COVID-19 severity. In Arm 2, patients will be recruited prospectively from local general practices (GPs) with measurement of vitamin D levels at enrolment. They will be followed up after 6 months to determine whether baseline vitamin D levels correspond with developing COVID-19. Data will be collected from a mixture of patient medical records, electronic patient records, laboratory data and from patients themselves. Data in Arm 1 will be analysed with a combination of linear and logistic regression, as appropriate, and with adjustment for covariates. Data in Arm 2 will be analysed as a case-control study, with adjustment for covariates.

The primary objectives are to determine whether vitamin D levels affect outcomes in COVID-19 infection and whether vitamin D deficiency is associated with increased risk.

Read the detailed description

STUDY DESIGN Arm 1: Hospital in-patients with a clinical diagnosis of COVID-19 This will be an observational cohort study of patients hospitalised at Tameside General Hospital with a clinical diagnosis of COVID-19, as defined by the clinical coding department. Patient identifiers will be extracted by the coding department and held on a secure server at Tameside Hospital. Identifiers will be used to ensure serum samples already taken as part of routine clinical management of these patients can be processed for a vitamin D level. No additional blood samples will need to be taken.

Patient demographic details will be extracted from their clinical notes and electronic patient records, then placed on an anonymised database for analysis. Data will be analysed to determine the following:

  1. Are vitamin D levels associated with outcomes/prognosis in patients hospitalised with COVID-19?
  2. Are vitamin D levels associated with ethnicity in patients hospitalised with COVID-19?
  3. Are vitamin D levels associated with comorbidity in patients hospitalised with COVID-19?

Projected recruitment is 200 patients to be opportunistically recruited who are undergoing usual clinical care for COVID-19.

Arm 2: Primary care patients prospectively studied with reference to baseline vitamin D and risk of COVID-19 Patients will be prospectively recruited from local GP surgeries within the Tameside and Glossop Clinical Commissioning Group. Patients will be consented by Good Clinical Practice (GCP)-certified practitioners. A serum sample will be collected on recruitment for a baseline vitamin D level to be obtained. Patient contact details will be collected, as well as baseline health status and comorbidities, then stored on an encrypted database on a secure server at Tameside Hospital. Vitamin D levels will be communicated to GP surgeries and GPs can decide whether to treat patients according to local treatment guidelines for suboptimal vitamin D. After 6 months, patients will be followed-up via telephone interview, in order to ascertain whether they have developed COVID-19, any treatment outcomes for this, and whether they have been treated with vitamin D in the interim in primary/secondary/tertiary care.

Data will be analysed once all recruited patients have been followed-up after 6 months. At follow-up, patients who have developed COVID-19 will be deemed to be cases, and those who have not will be deemed to be controls, for a case-control analysis using vitamin D levels as an exploratory covariate. It is anticipated that there will be some patient drop-out, but compliance with follow-up is likely to be high, due to the use of a telephone interview. Analysis will aim to determine whether vitamin D levels are associated with the risk of developing COVID-19, with reference to additional covariates, such as ethnicity and comorbidity.

Projected recruitment is 800 patients to be opportunistically recruited who are attending their GP surgery for routine care, not necessarily related to COVID-19.

INCLUSION CRITERIA Arm 1

Inclusion criteria:

  • Aged >=18 years.
  • Inpatient admitted to Tameside General Hospital.
  • Clinical diagnosis of COVID-19 - not necessary for SARS-CoV-2 swab to be positive.
  • Patients on vitamin D treatment to be included, but this will be adjusted for in analysis.

Exclusion criteria:

  • Aged \<18 years.
  • Final clinical diagnosis NOT COVID-19.

Arm 2

Inclusion criteria:

  • Aged >=18 years.
  • Patients on vitamin D treatment to be included, but this will be adjusted for in analysis.

Exclusion criteria:

  • Aged \<18 years.
  • On active treatment for malignancy/diagnosis of cancer within 6 months prior to enrolment.
  • Patients on immunosuppression.

ANALYSIS Arm 1

Mean values of age and gender, as well as proportions of different ethnic groups, will be used to assess group comparability. Primary analysis will involve linear regression of vitamin D levels (as a continuous variable, with adjustment for age and gender) against variables representing COVID-19 treatment outcomes:

  • Mode of oxygen therapy (low-flow \<10L/min, high-flow>=10L/min, nasal high-flow, CPAP, endotracheal intubation).
  • Treatment history (excluding oxygen therapy).
  • Discharge.
  • Death.

Primary analysis will also include logistic regression of ethnic groups against the above treatment outcome variables, with adjustment for age, gender and vitamin D status.

The following variables will be included as additional predictors of severity:

  • Admission SpO2.
  • Chest x-ray findings on admission.
  • CRP on admission.
  • D-dimer on admission.
  • Creatinine on admission.
  • Adjusted calcium on admission.
  • Treatment with vitamin D.
  • Ethnicity.

The following variables will be included as covariates:

  • Age.
  • Gender.
  • Comorbidities.
  • BMI.
  • Presence of diabetes.
  • SARS-CoV-2 swab result.

Linear regression will be reported as a coefficient with a 95% confidence interval. Logistic regression will be reported as an adjusted odds ratio with a 95% confidence interval. Missing data will be imputed. Analysis will be carried out once all data has been collected for n=200 patients and serum vitamin D levels are available.

Arm 2

Mean values of age and gender, as well as proportions of different ethnic groups, will be used to assess group comparability. Once all data has been collected, patients who developed COVID-19 will be defined as "cases" and those who did not will be defined as "controls." A case-control study including vitamin D as a predictor variable will then be carried out, with statistics reported as an adjusted odds ratio with a 95% confidence interval. Further subanalysis will be carried out on the following outcome measures (again, being defined as a "case"):

  • Hospitalisation with COVID-19.
  • Discharge from hospital following treatment for COVID-19.
  • Death from COVID-19.

The following variables will be included as additional predictors of severity:

  • Treatment with vitamin D.
  • Ethnicity.

The following variables will be included as covariates:

  • Age.
  • Gender.
  • Comorbidities.
  • BMI.
  • Presence of diabetes.

Missing data at enrolment will be imputed. Patients lost to follow-up will have baseline data included and they will be treated as a "control." Analysis will be carried out once all follow-up data has been collected for n=800 patients recruited.

03

Conditions studied

  • COVID-19
  • Vitamin D Deficiency

Keywords

  • COVID-19
  • SARS-CoV-2
  • Novel coronavirus
  • Vitamin D
  • Ethnicity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

ARM 1 Patients will be opportunistically recruited from in-patient admissions with a clinical diagnosis of COVID-19 as registered by the Trust's clinical coding department. This will be carried out at a single centre (Tameside and Glossop Integrated Care NHS Foundation Trust).

ARM 2 Patients will be opportunistically recruited from 10 local GP surgeries feeding into the acute Trust, as part of the Tameside and Glossop Clinical Commissioning Group.

Eligibility criteria

ARM 1 - hospital in-patients

Inclusion Criteria:

  • In-patient admitted to Tameside General Hospital.
  • Clinical diagnosis of COVID-19 - not necessary for SARS-CoV-2 swab to be positive.
  • Patients on vitamin D treatment to be included, but this will be adjusted for in analysis.

Exclusion Criteria:

  • Final clinical diagnosis NOT COVID-19.

ARM 2 - prospective primary care case-control study

Inclusion Criteria:

  • Patients on vitamin D treatment to be included, but this will be adjusted for in analysis.

Exclusion Criteria:

  • On active treatment for /diagnosis of cancer within 6 months prior to enrolment.
  • Patients on e.g. for disease, for solid organ transplant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
986 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Hospital in-patients

    Cross-sectional study of hospital in-patients admitted with COVID-19 n=200

  • Controls (case-control study arm)

    Case-control study of n=800 patients prospectively recruited from primary care

  • Cases (case-control study arm)

    Case-control study of n=800 patients prospectively recruited from primary care

06

What researchers measure

Primary outcomes

  1. COVID-19 infection

    Development of COVID-19 during case-control study

    Time frame: 1 year

  2. Oxygen therapy for COVID-19

    Whether hospitalised COVID-19 patients require oxygen therapy

    Time frame: 1 year

  3. Discharge following COVID-19 hospitalisation

    Whether patients hospitalised with COVID-19 were discharged

    Time frame: 1 year

  4. Death due to COVID-19

    Whether patients hospitalised with COVID-19 died in hospital

    Time frame: 1 year

07

Study locations

1 site
  • Tameside Hospital NHS Foundation Trust
    Ashton-under-Lyne, Greater Manchester OL6 9RW, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Aug 2020, 2 months.

Of 1,641 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 2 months is below that.

Counting every sponsor, half of 1,775 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2020
First posted
May 13, 2020
StartActual
Jun 1, 2020
Primary completionActual
Aug 8, 2020
CompletionActual
Sep 8, 2020
Last update
May 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04386044
Lead sponsor
Tameside General Hospital
Responsible party
Sponsor
First posted
May 13, 2020
Start date
Jun 1, 2020
Primary completion
Aug 8, 2020
Completion
Sep 8, 2020
Last update
May 7, 2021

Study contacts

Margaret Cooper
study director · Tameside and Glossop Integrated Care NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion